My life & career
Cheaper genomic measurement may expand options, but useful interpretation still needs clinicians and carefully validated evidence.
YOTTABIT / THE BIG STORIES / Biology
What if reading human DNA became the easy part?
The price of sequencing DNA has fallen spectacularly over the past two decades. But reading the letters in the genome is not the same as understanding what they mean, or turning that understanding into a safe treatment.
THE BIG PICTURE
Imagine a future in which a doctor's challenge is less about obtaining biological information and more about interpreting it wisely. That shift could make new approaches to diagnostics and personalized care possible.
Biology remains extraordinarily complex. Meaningful clinical outcomes demand testing, expertise, privacy protection and access.
THE YOTTABIT PERSPECTIVE
What does it mean to me?
Big change is fascinating. Its implications are what matter.
My business
The growth opportunity may lie in trusted interpretation, privacy protection, diagnostics and patient pathways—not sequencing alone.
My industry
Healthcare, pharmaceutical research and agriculture can increasingly treat biological information as an input to discovery.
FROM JIM CARROLL’S WORK
Jim’s healthcare work follows the movement from sick care toward predictive, personalized and connected care.
Meet the futurist behind YottaBit ↗WHAT COULD I DO MONDAY MORNING?
Ask which decision would change if you could obtain a genomic answer faster—and what confirmation would be required.
CURIOUS FOR MORE?
Explore the story behind the story.
For those who want the deeper explanation, the research is always available. The fascinating possibilities are only the beginning.
Research, explanations and sources EXPLORE THE DETAILS +
A remarkable measured cost curve
The US National Human Genome Research Institute tracks costs at sequencing centers using carefully defined production methods. Research reports compare roughly $95 million per human genome in 2001 with costs in the hundreds of dollars two decades later. The historical decline is extraordinary, but those production costs do not include everything needed for interpretation, diagnosis or treatment.
From reading to interpreting
Faster and cheaper sequencing creates data. It does not, by itself, explain which variants are medically important, how genes interact with environments, or what intervention will help a patient. Clinical validation, evidence of mechanism, regulation, consent and access remain hard problems.
The convergence opportunity
AI models, single-cell data, spatial biology and automated experiments enlarge the set of questions that can be explored. The strongest evidence of progress will be improvements in validated diagnosis, discovery quality and patient outcomes—not only the volume of sequences generated.